Sichuan Huiyu Pharmaceutical (688553.SH): HYP-6589 Tablets' Combination Therapy Receives Clinical Trial Application Acceptance

Stock News

Nov 21, 2025

Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SH) announced that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. ("Huiyu Haiyue"), received the "Acceptance Notice" issued by the National Medical Products Administration (NMPA) on November 21, 2025. The clinical trial application for HYP-6589 tablets (R&D code: HY-0006) in combination with osimertinib for the treatment of advanced non-small cell lung cancer (NSCLC) with target-driven gene positivity has been accepted.

HYP-6589 tablets, developed by Huiyu Haiyue, are a highly selective SOS1 small-molecule inhibitor classified as a Class 1 innovative chemical drug. According to the NMPA's "Classification and Application Requirements for Chemical Drug Registration" (No. 44, 2020), HYP-6589 is a structurally novel compound with pharmacological activity. The company has already obtained approval and is conducting clinical research in China for HYP-6589 as a monotherapy for advanced solid tumors. This new application seeks to expand its use in combination with osimertinib for advanced NSCLC with target-driven gene positivity.

As of the announcement date, no similar products have been approved for marketing domestically or internationally.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1110986196"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1110986196\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1110986196?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-21 17:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1110986196","market":"sg","top_or_hot":-1,"title":"Sichuan Huiyu Pharmaceutical (688553.SH): HYP-6589 Tablets' Combination Therapy Receives Clinical Trial Application Acceptance","media":"Stock News","content":"<p>Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SH) announced that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. (\"Huiyu Haiyue\"), received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA) on November 21, 2025. The clinical trial application for HYP-6589 tablets (R&D code: HY-0006) in combination with osimertinib for the treatment of advanced non-small cell lung cancer (NSCLC) with target-driven gene positivity has been accepted.</p>\n<p>HYP-6589 tablets, developed by Huiyu Haiyue, are a highly selective SOS1 small-molecule inhibitor classified as a Class 1 innovative chemical drug. According to the NMPA's \"Classification and Application Requirements for Chemical Drug Registration\" (No. 44, 2020), HYP-6589 is a structurally novel compound with pharmacological activity. The company has already obtained approval and is conducting clinical research in China for HYP-6589 as a monotherapy for advanced solid tumors. This new application seeks to expand its use in combination with osimertinib for advanced NSCLC with target-driven gene positivity.</p>\n<p>As of the announcement date, no similar products have been approved for marketing domestically or internationally.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Huiyu Pharmaceutical (688553.SH): HYP-6589 Tablets' Combination Therapy Receives Clinical Trial Application Acceptance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Huiyu Pharmaceutical (688553.SH): HYP-6589 Tablets' Combination Therapy Receives Clinical Trial Application Acceptance\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-11-21 17:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SH) announced that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. (\"Huiyu Haiyue\"), received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA) on November 21, 2025. The clinical trial application for HYP-6589 tablets (R&D code: HY-0006) in combination with osimertinib for the treatment of advanced non-small cell lung cancer (NSCLC) with target-driven gene positivity has been accepted.</p>\n<p>HYP-6589 tablets, developed by Huiyu Haiyue, are a highly selective SOS1 small-molecule inhibitor classified as a Class 1 innovative chemical drug. According to the NMPA's \"Classification and Application Requirements for Chemical Drug Registration\" (No. 44, 2020), HYP-6589 is a structurally novel compound with pharmacological activity. The company has already obtained approval and is conducting clinical research in China for HYP-6589 as a monotherapy for advanced solid tumors. This new application seeks to expand its use in combination with osimertinib for advanced NSCLC with target-driven gene positivity.</p>\n<p>As of the announcement date, no similar products have been approved for marketing domestically or internationally.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HYP","symbol_name":"Golden Eagle Dynamic Hypergrowth ETF","start_time":0,"source_url":"","article_id":"1110986196","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1110986196","pubTimestamp":1763715862,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SH) announced that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. (\"Huiyu Haiyue\"), received the \"Acceptance...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688553":"汇宇制药","HYP":"Golden Eagle Dynamic Hypergrowth ETF","BK0239":"医药制造"},"translate_title":"四川汇宇药业（688553.SH）：HYP-6589片联合疗法获临床试验申请受理","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688553":1,"HYP":1},"content_text":"Sichuan Huiyu Pharmaceutical Co., Ltd. (688553.SH) announced that its wholly-owned subsidiary, Sichuan Huiyu Haiyue Pharmaceutical Technology Co., Ltd. (\"Huiyu Haiyue\"), received the \"Acceptance Notice\" issued by the National Medical Products Administration (NMPA) on November 21, 2025. The clinical trial application for HYP-6589 tablets (R&D code: HY-0006) in combination with osimertinib for the treatment of advanced non-small cell lung cancer (NSCLC) with target-driven gene positivity has been accepted.\nHYP-6589 tablets, developed by Huiyu Haiyue, are a highly selective SOS1 small-molecule inhibitor classified as a Class 1 innovative chemical drug. According to the NMPA's \"Classification and Application Requirements for Chemical Drug Registration\" (No. 44, 2020), HYP-6589 is a structurally novel compound with pharmacological activity. The company has already obtained approval and is conducting clinical research in China for HYP-6589 as a monotherapy for advanced solid tumors. This new application seeks to expand its use in combination with osimertinib for advanced NSCLC with target-driven gene positivity.\nAs of the announcement date, no similar products have been approved for marketing domestically or internationally.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}